약제용출성 풍선 카테터 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Drug-Eluting Balloon Catheters Market was valued at USD 637.8 million in 2024 and is projected to grow at a CAGR of 9.9% from 2025 to 2034. This expansion is primarily driven by the rising prevalence of peripheral and cardiovascular diseases, increasing preference for minimally invasive treatments, and the growing aging population worldwide.

Cardiovascular diseases (CVDs) such as coronary artery disease, strokes, and peripheral artery disease (PAD) have become a global health concern. Contributing factors include unhealthy lifestyles, aging populations, and the widespread occurrence of conditions like hypertension and diabetes. These factors have led to a surge in demand for minimally invasive procedures, with DEB catheters emerging as a preferred solution for managing arterial blockages and enhancing blood flow without the need for permanent implants.

DEB catheters, also known as drug-coated balloons, deliver antiproliferative drugs such as paclitaxel or sirolimus directly to the arterial walls during balloon expansion. This controlled drug release helps treat hyperplasia and improve outcomes in both peripheral and coronary vascular diseases. The market is segmented by product into coronary artery disease and peripheral vascular disease DEB catheters. In 2024, the peripheral vascular disease segment led the market, generating USD 353 million in revenue.

Peripheral vascular disease DEB catheters are particularly effective for complex lesions where stents may not be suitable. By reducing smooth muscle cell proliferation and preventing restenosis, these catheters maintain optimal blood flow and improve patient outcomes. The rising preference for minimally invasive interventions due to shorter recovery times and fewer complications has significantly contributed to the popularity of DEB catheters for peripheral vascular applications.

Material-wise, the market is categorized into polyurethane, nylon, and other materials. Polyurethane-based DEB catheters generated USD 225.4 million in revenue in 2024 and are expected to grow at a CAGR of 10.4% through 2034. Known for its flexibility, biocompatibility, and durability, polyurethane is ideal for navigating complex vascular structures, ensuring patient comfort, and reducing the risk of injury during procedures.

Hospitals and clinics accounted for the largest share of the market in 2024, driven by increasing admissions for cardiovascular and peripheral artery disorders. The segment is expected to reach USD 938.3 million by 2034, supported by the growing demand for advanced surgical care and minimally invasive interventions.

In terms of regional performance, North America dominated the market with USD 272.2 million in revenue in 2024. This growth is attributed to the region's advanced healthcare infrastructure, high prevalence of CVDs, and widespread adoption of DEB technology in interventional cardiology and vascular care.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of peripheral and cardiovascular diseases
    • 3.2.1.2 Technological advancements in drug-eluting balloon catheters
    • 3.2.1.3 Increasing preference for minimally invasive procedures
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of product
    • 3.2.2.2 Risk of infection associated with the use of drug-eluting balloon catheters
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Coronary artery disease drug-eluting balloon catheters
  • 5.2.1 Paclitaxel
  • 5.2.2 Sirolimus
• 5.3 Peripheral vascular disease drug-eluting balloon catheters
  • 5.3.1 Paclitaxel
  • 5.3.2 Sirolimus

Chapter 6 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Polyurethane
• 6.3 Nylon
• 6.4 Other materials

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory surgical centers
• 7.4 Catheterization laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Aachen Resonance GmbH
• 9.2 B. Braun
• 9.3 Becton, Dickinson and Company
• 9.4 Biosensors International
• 9.5 Biotronik AG
• 9.6 Boston Scientific Corporation
• 9.7 Eurocor GmbH
• 9.8 iVascular S.L.U.
• 9.9 Zhejiang Barty Medical Technology Co.Ltd
• 9.10 Lepu Medical Technology(Beijing) Co. Ltd.
• 9.11 MedAlliance
• 9.12 Medtronic plc